U.S. stocks rise on Fed cut bets; earnings continue to flow
MALVERN, Pa. - Endo, Inc. (OTCQX:NDOI), a $1.6 billion pharmaceutical company currently trading near its 52-week low, announced Thursday that it is presenting three studies related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) at the American Podiatric Medical Association Annual Meeting taking place July 24-27, 2025. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.96, despite operating with a significant debt burden.
The presentations include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum (CCH) in patients with PFA and PFI, respectively, as well as a retrospective analysis of patient experiences with PFI. With annual revenue of $1.73 billion and its next earnings report due on August 6, investors are closely watching these developments for potential catalysts.
A post hoc analysis of Phase 2 data identified a subgroup of PFI patients who showed improvements in pain, nodule hardness, and overall condition when treated with CCH compared to placebo. This refined patient population is now being studied in an ongoing Phase 3 trial.
The retrospective analysis of 91 PFI patients revealed that individuals reporting moderate to severe pain face greater physical, emotional, and daily life burdens, with participants expressing dissatisfaction with current treatments and interest in nonsurgical options.
In the Phase 1 proof-of-concept study for PFA, CCH treatment demonstrated improvements across effectiveness measures compared to placebo, with a safety profile consistent with known adverse events that were mostly mild to moderate.
"We’re pleased to share clinical trial data with healthcare providers as part of our ongoing efforts to help improve patient care," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo, in the press release.
PFI, also known as Ledderhose disease, involves the formation of collagen nodules along the plantar fascia, while PFA causes foot discomfort due to inflammation of the tissue connecting the heel to the toes.
CCH is not currently approved for treating either condition, according to the company’s statement. While Endo remains profitable over the last twelve months, InvestingPro analysis reveals additional insights about the company’s financial health and growth prospects, with over 30 additional metrics and exclusive ProTips available to subscribers.
In other recent news, Endo has completed the sale of its International Pharmaceuticals business to Knight Therapeutics Inc. This transaction, valued at up to $105 million, involved the Canada-based specialty pharmaceutical company Paladin Pharma Inc. The deal structure included an initial payment of approximately $79 million at closing. Additionally, there are $11 million in permitted holdbacks and up to $15 million in potential future payments, contingent on achieving specific milestones. This development marks a significant step for Endo as it reshapes its business strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.